Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-VEGF versus RPE-choroid graft in advanced age-related macular degeneration
2008-008259-41Phase 2Completed
- Sponsor
- Het Oogziekenhuis Rotterdam
- Start
- Dec 2008
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of bevacizumab and ranibizumab in age-related macular degeneration (AMD) (2 arms), sponsored by Het Oogziekenhuis Rotterdam. Primary endpoint: Visual acuity at 1 year. Started Dec 2008; status: completed.
02
Drugs
bevacizumabranibizumab
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on 2008-008259-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-008259-41.